Table 2.

Distribution of somatic mutations (presence vs. absence) detected by NGS according to clinico-pathologic characteristics of patients with HGSOC.

Characteristics	n = 64	TP53 n (%)	p	KRAS n (%)	p	FBXW7 n (%)	p	PTEN n (%)	p	APC n (%)	p	PIK3CA n (%)	p
Tumor Histology
Serous	64	49 (76.6)	-	4 (6.2)	-	2 (3.1)	-	2 (3.1)	-	1 (1.6)	-	1 (1.6)	-
FIGO Stage a
III	51	39 (76.5)	1.000	1 (2.0)	0.102	2 (3.9)	1.000	2 (3.9)	1.000	1 (2.0)	1.000	1 (2.0)	1.000
IV	13	10 (76.9)		2 (15.4)		0 (0.0)		0 (0.0)		0 (0.0)		0 (0.0)
Tumor Grade
G2	18	12 (66.7)	0.326	3 (16.7)	0.064	1 (5.5)	0.487	1 (5.5)	0.487	0 (0.0)	1.000	0 (0.0)	1.000
G3	46	37 (80.4)		1 (2.2)		1 (2.2)		1 (2.2)		1 (2.2)		1 (2.2)
RD at PDS
0	33	25 (75.7)	1.000	1 (3.0)	0.347	1 (3.0)	1.000	2 (6.1)	0.493	0 (0.0)	0.484	0 (0.0)	0.484
<1 cm	31	24 (77.4)		3 (9.7)		1 (3.2)		0 (0.0)		1 (3.2)		1 (3.2)
Platinum sensitivity b
Refractory	3	1 (33.3)	0.017	1 (33.3)	0.202	1 (33.3)	0.019	0 (0.0)	0.660	1 (33.3)	<0.001	0 (0.0)	0.502
Resistant	13	12 (92.3)		0 (0.0)		0 (0.0)		1 (7.7)		0 (0.0)		0 (0.0)
Intermediate	19	18 (94.7)		1 (5.3)		0 (0.0)		0 (0.0)		0 (0.0)		1 (5.3)
Sensitive	28	19 (67.8)		2 (7.1)		1 (3.6)		1 (3.6)		0 (0.0)		0 (0.0)

^a One patient with IIIB stage was included in IIIC (III vs. IV). ^b One patient was not evaluated due to loss at follow up. NGS: Next-generation sequencing; FIGO: Fédération Internationale de Ginécologie et d’Obstetrique; RD: residual disease; PDS: primary debulking surgery. Comparisons were performed using Fisher’s Exact test or Chi-squared test; according to Bonferroni, p value < 0.008 was considered significant and was depicted in bold.